Posted by Michael Wonder on 03 Mar 2022
Jemperli approved by the TGA
2 March 2022 - Dostarlimab is an anti-programmed cell death protein 1 immunoglobulin G4 humanised monoclonal antibody, derived from a stable Chinese hamster ovary cell line.
Jemperli is indicated as monotherapy for the treatment of adult patients with recurrent or advanced mismatch repair deficient endometrial cancer that has progressed on or following prior treatment with a platinum-containing regimen.
